Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ORC 13661

Next Previous
Drug Profile

ORC 13661

Alternative Names: DB 041; ORC-13661

Latest Information Update: 01 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oregon Health & Science University; University of Washington
  • Developer Oricula Therapeutics
  • Class Amides; Chlorobenzenes; Heterocyclic bicyclo compounds; Phenylurea compounds; Small molecules; Thiophenes
  • Mechanism of Action Cell death inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sensorineural hearing loss

Most Recent Events

  • 31 May 2025 Phase-II clinical trials in Sensorineural hearing loss (Prevention, Adjunctive treatment) in USA (PO) (NCT05730283)
  • 16 Jul 2024 ORC 13661 is still in phase I development in Sensorineural hearing loss (Prevention, In volunteers) in USA (PO) (Oricula Therapeutics pipeline, July 2024)
  • 15 Feb 2023 Oregon Health and Science University plans a phase II trial for amikacin induced sensorineural hearing loss (Prevention, Adjunctive treatment, In adults, In the elderly) in USA (PO, Capsule) (NCT05730283)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top